Brokerages Set Vor Biopharma Inc. (NASDAQ:VOR) Target Price at $50.56

Vor Biopharma Inc. (NASDAQ:VOR) has received an average rating of “Moderate Buy” from the thirteen analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $50.5556.

A number of brokerages recently commented on VOR. Jefferies Financial Group raised shares of Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. Citigroup started coverage on shares of Vor Biopharma in a research report on Friday, January 9th. They set a “buy” rating and a $50.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, January 21st. HC Wainwright lowered their price target on shares of Vor Biopharma from $32.00 to $31.00 and set a “buy” rating on the stock in a research report on Wednesday, April 15th. Finally, Wall Street Zen raised shares of Vor Biopharma from a “strong sell” rating to a “hold” rating in a research note on Saturday, April 4th.

Vor Biopharma Stock Performance

Vor Biopharma stock opened at $15.52 on Friday. Vor Biopharma has a fifty-two week low of $2.62 and a fifty-two week high of $65.80. The firm has a market capitalization of $841.03 million, a price-to-earnings ratio of -0.04 and a beta of 1.75. The stock’s fifty day moving average is $15.02 and its two-hundred day moving average is $14.81.

Insider Buying and Selling

In other Vor Biopharma news, Director Ra Capital Management, L.P. sold 165,150 shares of the firm’s stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $15.77, for a total transaction of $2,604,415.50. Following the completion of the transaction, the director owned 2,402,095 shares of the company’s stock, valued at approximately $37,881,038.15. This trade represents a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In the last 90 days, insiders sold 3,002,903 shares of company stock worth $49,412,176. 0.45% of the stock is currently owned by corporate insiders.

Institutional Trading of Vor Biopharma

A number of large investors have recently made changes to their positions in the stock. Ariose Capital Management Ltd acquired a new position in Vor Biopharma in the 3rd quarter valued at about $5,368,000. Fcpm Iii Services B.V. acquired a new stake in shares of Vor Biopharma during the 3rd quarter worth about $18,496,000. Jane Street Group LLC purchased a new stake in shares of Vor Biopharma during the first quarter worth about $140,000. Susquehanna Portfolio Strategies LLC purchased a new stake in shares of Vor Biopharma during the fourth quarter worth about $134,000. Finally, XTX Topco Ltd acquired a new position in shares of Vor Biopharma in the second quarter valued at approximately $66,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).